PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Both companies show declining cash positions (-8.57% vs TRVN's -17.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Below half of TRVN's -17.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Other current assets growth 50-75% of TRVN's -23.50%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-8.67%
Below half of TRVN's -18.28%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.20%
1.25-1.5x TRVN's -5.92%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Higher Other Non-Current Assets Growth compared to TRVN's zero value, indicating worse performance.
-7.12%
0.75-0.9x TRVN's -9.34%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
0.5-0.75x TRVN's -16.37%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-100.00%
Above 1.5x TRVN's -18.90%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Above 1.5x TRVN's -15.86%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Exceeding 1.5x TRVN's 100.00%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-20.28%
Less than half of TRVN's 16.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
50-75% of TRVN's -0.77%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Less than half of TRVN's 1.42%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
0.5-0.75x TRVN's -22.96%. Martin Whitman is wary of lagging equity growth vs. competitor.
-8.62%
0.5-0.75x TRVN's -16.37%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Similar yoy to TRVN's -100.00%. Walter Schloss notes parallel moves in the investment portfolio.
-7.46%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
8.60%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.